Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Earnings Results

Verrica Pharmaceuticals (NASDAQ:VRCA) posted its quarterly earnings results on Tuesday. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18, FiscalAI reports. The business had revenue of $5.02 million for the quarter, compared to analyst estimates of $4.51 million.

Here are the key takeaways from Verrica Pharmaceuticals’ conference call:

• Verrica said YCANTH demand accelerated in Q1, with U.S. revenue up 25.4% year over year and dispensed applicator units up 51.3%, including record monthly volume in March and further growth in April.
• The company highlighted commercial expansion efforts such as the YcanthRx pharmacy model, a growing sales force, and improved access tools that management believes are helping drive adoption and reimbursement.
• Verrica reported meaningful progress in its common warts Phase III program, with more than 50% of targeted enrollment reached in COVE-2 and plans to start COVE-3 by mid-2026.
• The company continues to advance VP-315 for basal cell carcinoma, pointing to strong Phase II data, regulatory alignment, and market research that suggests potential acceptance as a non-surgical or neoadjuvant option.
• Financially, Verrica ended the quarter with $20.6 million in cash and said that balance is expected to fund operations into the first quarter of 2027, while the quarterly net loss remained roughly flat year over year.

Verrica Pharmaceuticals Price Performance

Shares of VRCA stock opened at $7.37 on Thursday. The stock’s fifty day simple moving average is $6.02 and its 200 day simple moving average is $6.31. Verrica Pharmaceuticals has a one year low of $3.28 and a one year high of $9.82. The firm has a market cap of $126.62 million, a price-to-earnings ratio of -7.16 and a beta of 1.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.59 and a quick ratio of 2.45.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Affinity Asset Advisors LLC acquired a new stake in shares of Verrica Pharmaceuticals in the 4th quarter valued at $5,878,000. Velan Capital Investment Management LP bought a new position in Verrica Pharmaceuticals during the 4th quarter valued at about $3,919,000. Boothbay Fund Management LLC bought a new position in Verrica Pharmaceuticals during the 3rd quarter valued at about $1,210,000. Kalehua Capital Management LLC acquired a new position in Verrica Pharmaceuticals in the fourth quarter valued at about $1,959,000. Finally, Marshall Wace LLP acquired a new position in Verrica Pharmaceuticals in the second quarter valued at about $66,000. 42.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Zacks Research raised shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday. Wall Street Zen cut shares of Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $17.00.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off?label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next?generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.